Unicycive Therapeutics
UNCY
51 hedge funds and large institutions have $65.2M invested in Unicycive Therapeutics in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 2 closing their positions.
900% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 2
50% more funds holding
Funds holding: 34 → 51 (+17)
39% more capital invested
Capital invested by funds: $47M → $65.2M (+$18.2M)
8.2% more ownership
Funds ownership: 37.9% → 46.09% (+8.2%)
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
68% less call options, than puts
Call options by funds: $1.13M | Put options by funds: $3.51M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.52M |
| 2 |
IHAM
Integral Health Asset Management
New York
|
+$1.47M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.14M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$1.02M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$937K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
-$819K |
| 2 |
Squarepoint
New York
|
-$319K |
| 3 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$303K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$141K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$83.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DB
51
Danske Bank
Copenhagen K,
Denmark
| $7 | – | – | – |
|
|
52
Squarepoint
New York
| – | -$319K | -55,305 | Closed |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| – | -$11.1K | -1,920 | Closed |
|
UNCY Hedge Fund Activity: Q1 2026 in Review
51 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q1 2026, worth a combined $65.2M — up 39% from $47M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new UNCY positions and 2 closed out — a net gain of 18 holders — while 10 added to existing stakes and 11 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.52M. The largest seller was Cantor Fitzgerald, cutting an estimated $819K.
- 51 institutional investors held Unicycive Therapeutics (UNCY) as of Q1 2026, up from 34 in Q4 2025.
- Funds reported $65.2M of Unicycive Therapeutics stock for Q1 2026, up 39% quarter-over-quarter.
- 20 funds opened new Unicycive Therapeutics positions in Q1 2026 and 2 closed out, a net change of +18 holders.
- The largest Unicycive Therapeutics buyer in Q1 2026 was Millennium Management, an estimated $2.52M added.
- The largest Unicycive Therapeutics seller in Q1 2026 was Cantor Fitzgerald, an estimated $819K sold.
Based on aggregated 13F filings for Q1 2026.